• For Individuals
  • For Institutions
  • Download
  • Help

  • About

longbridgelongbridge
longbridgelongbridge
Why Longbridge?
Investment Products
Trading Tools
Trading Platform
Developers
Market Data Services
Analysis Tools
News Services
Dolphin Research
Pricing
Markets
Global Markets
Stock Screener
Information
Research
News
Live
Community
Academy
Promotions
EN
English
简体中文
繁體中文
繁體中文（廣東話）Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
Posts
News
Financials

Event Tracking

Nov3
Junshi Biosciences Announces Q3 2025 Report: Increased Sales Revenue of Toripalimab
12:52
Nov2
Huang Renxun's Watchlisted Stocks and Shanghai Junshi Biotech Rating
16:46
Oct28
JUNSHI BIOPHARMA reports Q3 revenue growth but continues to post losses
09:55
Junshi Biosciences released FY2025 9 Months Earnings on October 28 After-Market (BJT), actual revenue CNY 1.806 B, actual EPS CNY -0.6008
01:00
Junshi Biosciences released FY2025 Q3 earnings on October 28 After-Market BJT, actual revenue CNY 637.5 M, actual EPS CNY -0.1806
01:00
Oct22
Jushi Biopharma Subsidiary Passes FDA CGMP Inspection
09:05

Schedules & Filings

Schedules
Filings
Oct28
Earning Release(CST)

FY2025 Q3 Earning Release (CNY) Revenue 637.5 M, Net Income -183 M, EPS -0.1806

Aug26
Earning Release(CST)

FY2025 Q2 Earning Release (CNY) Revenue 667.79 M, Net Income -177.82 M, EPS -0.1802

Apr25
Earning Release(CST)

FY2025 Q1 Earning Release (CNY) Revenue 500.59 M, Net Income -234.88 M, EPS -0.24

View More

Stock List

Top Gainers
Top Decliners
Northbound Connect
Symbol
Price
%Chg
Change
View More
Terms & Conditions
  • Terms of Service
  • Privacy Policy